MX2023013246A - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo. - Google Patents

Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo.

Info

Publication number
MX2023013246A
MX2023013246A MX2023013246A MX2023013246A MX2023013246A MX 2023013246 A MX2023013246 A MX 2023013246A MX 2023013246 A MX2023013246 A MX 2023013246A MX 2023013246 A MX2023013246 A MX 2023013246A MX 2023013246 A MX2023013246 A MX 2023013246A
Authority
MX
Mexico
Prior art keywords
treating
same
cognitive disorders
preventing cognitive
agent
Prior art date
Application number
MX2023013246A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Akira Tanokura
Takashi Murakami
Naoko Namiki
Jeanne E Baker
Batteur Sophie Parmentier
Angela Marie Jablonski
Daniel Stephen Malashock
Carl Mieczkowski
Gopalan Raghunathan (Ranghu)
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2023013246A publication Critical patent/MX2023013246A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona métodos para usar y composiciones de anticuerpos humanizados que se unen a la proteína tau que está fosforilada en la serina en la posición 413.
MX2023013246A 2017-02-27 2019-08-20 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo. MX2023013246A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017035594A JP2018139530A (ja) 2017-02-27 2017-02-27 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Publications (1)

Publication Number Publication Date
MX2023013246A true MX2023013246A (es) 2023-11-21

Family

ID=62025891

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009945A MX2019009945A (es) 2017-02-27 2018-02-27 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo.
MX2023013246A MX2023013246A (es) 2017-02-27 2019-08-20 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019009945A MX2019009945A (es) 2017-02-27 2018-02-27 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo.

Country Status (26)

Country Link
US (3) US10556950B2 (es)
EP (1) EP3585810A1 (es)
JP (3) JP2018139530A (es)
KR (1) KR20190122674A (es)
CN (2) CN111320695B (es)
AR (2) AR110875A1 (es)
AU (1) AU2018224390A1 (es)
BR (1) BR112019016490A2 (es)
CA (1) CA3052538A1 (es)
CL (2) CL2019002296A1 (es)
CO (1) CO2019008786A2 (es)
CR (1) CR20190363A (es)
DO (1) DOP2019000215A (es)
EA (1) EA201991726A1 (es)
GE (1) GEP20227392B (es)
IL (1) IL267945A (es)
JO (1) JOP20180014A1 (es)
MA (1) MA47608A (es)
MX (2) MX2019009945A (es)
MY (1) MY193821A (es)
NI (1) NI201900086A (es)
PE (1) PE20191614A1 (es)
PH (1) PH12019501929A1 (es)
SG (2) SG10201913419TA (es)
TW (1) TW201843179A (es)
WO (2) WO2018154392A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
CA3148740A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
MX2022015133A (es) * 2020-06-02 2023-01-11 Teijin Pharma Ltd Anticuerpo humanizado anti-receptor de igf-1.
US20230265175A1 (en) * 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
JP4754352B2 (ja) 2003-08-29 2011-08-24 株式会社リバース・プロテオミクス研究所 タンパク質の固定化方法
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
MY164376A (en) * 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
EA031698B1 (ru) * 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
AU2012359039B2 (en) 2011-12-20 2017-08-24 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
SG10201805410XA (en) 2012-05-31 2018-08-30 Univ Osaka City Therapeutic agent or prophylactic agent for dementia
BR112015003326A2 (pt) * 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
US9598484B2 (en) 2012-12-21 2017-03-21 Biogen Ma Inc. Human anti-tau antibodies
EA039554B1 (ru) 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
CN105899533B (zh) 2013-12-20 2019-10-11 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
UA124616C2 (uk) 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Also Published As

Publication number Publication date
US20200223916A1 (en) 2020-07-16
EP3585810A1 (en) 2020-01-01
CN110382528A (zh) 2019-10-25
US11739143B2 (en) 2023-08-29
DOP2019000215A (es) 2019-09-30
AR117952A2 (es) 2021-09-08
EA201991726A1 (ru) 2020-01-30
JP7165996B2 (ja) 2022-11-07
JP2023002670A (ja) 2023-01-10
BR112019016490A2 (pt) 2020-04-07
AU2018224390A1 (en) 2019-07-11
CA3052538A1 (en) 2018-08-30
CN111320695A (zh) 2020-06-23
MX2019009945A (es) 2019-11-05
CR20190363A (es) 2019-11-05
NI201900086A (es) 2019-10-08
CO2019008786A2 (es) 2019-08-20
MA47608A (fr) 2020-01-01
JOP20180014A1 (ar) 2019-01-30
TW201843179A (zh) 2018-12-16
IL267945A (en) 2019-09-26
PE20191614A1 (es) 2019-11-05
MY193821A (en) 2022-10-27
GEP20227392B (en) 2022-06-27
KR20190122674A (ko) 2019-10-30
US20210380677A1 (en) 2021-12-09
AR110875A1 (es) 2019-05-08
CL2021002389A1 (es) 2022-04-22
US10556950B2 (en) 2020-02-11
CN111320695B (zh) 2021-09-03
US10894829B2 (en) 2021-01-19
JP2018139530A (ja) 2018-09-13
WO2018154392A1 (en) 2018-08-30
SG10201913419TA (en) 2020-03-30
WO2018154390A1 (en) 2018-08-30
CL2019002296A1 (es) 2019-11-29
PH12019501929A1 (en) 2020-06-29
US20180346564A1 (en) 2018-12-06
JP2020508666A (ja) 2020-03-26
SG11201907548PA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
PH12019501929A1 (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
EP3826612A4 (en) NOVEL MONOCLONAL ANTIBODIES SPECIFIC TO CLDN 18.2 AND THEIR METHODS OF USE
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
GEP20237484B (en) Antibody variants
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
CR20210332A (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización